Parkinson's DiseaseNCT07380737
Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
A study testing Walking Tall App in people with Parkinson's Disease, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
Trial summary
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Parkinson's Disease
- What is being tested?
- Walking Tall App
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteIsrael
- Study dates
- 29 Dec 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical diagnosis of idiopathic Parkinson's disease (MDS criteria);
- Hoehn \& Yahr stage II-III (ON-medication state);
- Able to walk independently for ≥5 minutes;
- Stable medication for ≥1 month;
- Currently enrolled in a rehab program at Ezra LeMarpe;
- Able to provide written informed consent;
Who cannot join
- Musculoskeletal, neurological, or visual/hearing impairments affecting gait;
- Cognitive impairments or severe behavioral symptoms;
- History of stroke, severe TBI, or brain tumor;
- Cardiovascular contraindications;
- Inability to use a smartphone;
- Participation in other concurrent intervention studies.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Tatyana Gurevich, Prof contact
Israel1 site, 1 recruiting
- Recruiting
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
Tel Aviv, 6423906
Sourasky Medical Cente, +972-3-6974000, ichilov-intru@tlvmc.gov.il
About this study
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.
Read the detailed description
This open-label, single-arm feasibility study will recruit 30 participants with idiopathic Parkinson's disease, currently enrolled in a rehabilitation program at the Ezra LeMarpe Organization in Israel. Participants will perform 4-5 walking sessions per week for 6 weeks using the Walking Tall smartphone application. The app delivers rhythmic cueing and motivational prompts to enhance walking speed, stride length, and confidence. The study includes baseline and post-intervention assessments. Walking behavior will be monitored using a tri-axial accelerometer worn for 7 days at each timepoint. The primary aim is to evaluate feasibility, adherence, and changes in daily walking activity, with secondary outcomes addressing gait parameters and user satisfaction. Findings will guide the design of future randomized controlled trials.
- Conditions
- Parkinson's Disease
- Being tested
- Walking Tall App
- Keywords
- Gait, Parkinson's Disease, Walking App, Rhythmic auditory cueing
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Walking Tall AppBehavioural
Participants will use the Walking Tall smartphone app to complete 4-5 home-based walking sessions per week for 6 weeks. The app provides rhythmic auditory cues and verbal prompts to improve gait quality.
| Study group | Role | What they receive |
|---|---|---|
| Walking Tall App Intervention | Experimental | Participants will use the Walking Tall smartphone app to complete 4-5 home-based walking sessions per week for 6 weeks. The app provides rhythmic auditory cues and verbal prompts to improve gait quality. Receives: Behavioral: Walking Tall App |
What is being measured
The primary outcome is the main question the study is designed to answer.
Average Step Count Per Day
Measured via accelerometer
Measured: Time Frame: Baseline and 6 weeks
Daily Walking Duration (minutes/week)
Measured using tri-axial accelerometer (Axivity) over 7 days
Measured: Time Frame: Baseline and 6 weeks
Secondary outcomes (3)
Gait Speed (m/s) - single- and dual-task
Assessed using a 1-minute walking test under two conditions: (1) single-task (normal walking) and (2) dual-task (walking while performing a cognitive task such as serial subtraction). Gait speed is calculated in meters per second based on distance walked over time in each condition.
Measured: Time Frame: Baseline and 6 weeks
Short Physical Performance Battery (SPPB)
The SPPB is a standardized test that evaluates lower extremity function using three components: balance (side-by-side, semi-tandem, tandem stance), gait speed over a 4-meter walk, and chair stands. Each component is scored from 0 to 4, with a total score ranging from 0 (worst performance) to 12 (best performance).
Measured: Time Frame: Baseline and 6 weeks
Timed Up and Go (TUG) - single- and dual-task
The TUG test measures functional mobility by timing how long it takes a participant to stand up from a chair, walk 3 meters, turn, return, and sit down. It is performed under two conditions: (1) single-task (normal walking) and (2) dual-task (walking while performing a cognitive task, such as serial subtraction). The test evaluates gait, balance, and cognitive-motor integration.
Measured: Time Frame: Baseline and 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start29 Dec 2025
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- More trials run by Tel-Aviv Sourasky Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Interventional Model: Single Group Assignment
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tel-Aviv Sourasky Medical Center
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Tatyana Gurevich, Prof, Principal investigator, Head of the Movement Disorders Unit at Ichilov Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07380737
- Sponsor's protocol ID
- 0481_25_TLV_TG
- Status last verified
- Feb 2026
- First submitted
- 25 Jan 2026
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Brodie, M. A., & University of New South Wales. (2023, August 7). New app is a step towards helping people with Parkinson's disease walk more confidently. UNSW Newsroom. Retrieved from https://www.unsw.edu.au/newsroom/news/2023/08/new-app-is-a-step-towards-helping-people-with-parkinsons-disease
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot Study
- ClinicalTrials.gov ID
- NCT07380737
- Acronym / sponsor ID
- 0481_25_TLV_TG
- Conditions
- Parkinson's Disease
- Keywords
- Gait, Parkinson's Disease, Walking App, Rhythmic auditory cueing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Tel-Aviv Sourasky Medical CenterOther government
- Study start
- 29 Dec 2025 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot study designed to assess the feasibility, adherence, and preliminary effects of a 6-week home-based gait training intervention using the Walking Tall mobile app in individuals with Parkinson's disease. The app delivers rhythmic auditory cues and motivational verbal prompts to promote gait improvements. Primary outcomes include daily walking duration and step count measured via wearable sensors; secondary outcomes include gait speed, balance, self-reported confidence, and usability.
Detailed description
This open-label, single-arm feasibility study will recruit 30 participants with idiopathic Parkinson's disease, currently enrolled in a rehabilitation program at the Ezra LeMarpe Organization in Israel. Participants will perform 4-5 walking sessions per week for 6 weeks using the Walking Tall smartphone application. The app delivers rhythmic cueing and motivational prompts to enhance walking speed, stride length, and confidence. The study includes baseline and post-intervention assessments. Walking behavior will be monitored using a tri-axial accelerometer worn for 7 days at each timepoint. The primary aim is to evaluate feasibility, adherence, and changes in daily walking activity, with secondary outcomes addressing gait parameters and user satisfaction. Findings will guide the design of future randomized controlled trials.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Interventional Model: Single Group Assignment
| Arm | Type | Receives |
|---|---|---|
| Walking Tall App Intervention | Experimental | Behavioral: Walking Tall AppParticipants will use the Walking Tall smartphone app to complete 4-5 home-based walking sessions per week for 6 weeks. The app provides rhythmic auditory cues and verbal prompts to improve gait quality. |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Clinical diagnosis of idiopathic Parkinson's disease (MDS criteria);
- Hoehn \& Yahr stage II-III (ON-medication state);
- Able to walk independently for ≥5 minutes;
- Stable medication for ≥1 month;
- Currently enrolled in a rehab program at Ezra LeMarpe;
Key exclusion criteria (6 listed)
- Musculoskeletal, neurological, or visual/hearing impairments affecting gait;
- Cognitive impairments or severe behavioral symptoms;
- History of stroke, severe TBI, or brain tumor;
- Cardiovascular contraindications;
- Inability to use a smartphone;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Walking Tall AppParticipants will use the Walking Tall smartphone app to complete 4-5 home-based walking sessions per week for 6 weeks. The app provides rhythmic auditory cues and verbal prompts to improve gait quality. | Behavioural | Walking Tall App Intervention |
Primary outcome
Average Step Count Per Day
Time frame: Time Frame: Baseline and 6 weeks
Measured via accelerometer
Daily Walking Duration (minutes/week)
Time frame: Time Frame: Baseline and 6 weeks
Measured using tri-axial accelerometer (Axivity) over 7 days
3 secondary outcomes
Gait Speed (m/s) - single- and dual-task
Time frame: Time Frame: Baseline and 6 weeks
Short Physical Performance Battery (SPPB)
Time frame: Time Frame: Baseline and 6 weeks
Timed Up and Go (TUG) - single- and dual-task
Time frame: Time Frame: Baseline and 6 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
- BackgroundBrodie, M. A., & University of New South Wales. (2023, August 7). New app is a step towards helping people with Parkinson's disease walk more confidently. UNSW Newsroom. Retrieved from https://www.unsw.edu.au/newsroom/news/2023/08/new-app-is-a-step-towards-helping-people-with-parkinsons-disease
- Individual participant dataSharing planned: No
Related trials for Parkinson's Disease
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Compulsive Eating and Brain's Reward System in Different Pathologies
PARKINSON DISEASE (Disorder), Bipolar 1 Disorder
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tatyana Gurevich, Prof contact
Tatyana Gurevich, Prof principal investigator
Head of the Movement Disorders Unit at Ichilov Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Walking Tall App in people with Parkinson's Disease, run by Tel-Aviv Sourasky Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Marina Brozgol, MS (+972-3-6947514, marinab@tlvmc.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Average Step Count Per Day (time frame: Time Frame: Baseline and 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07380737, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026; AzTrials last refreshed its copy on 7 Nov 2026.